Aux Labs, a Canadian startup making animal-free dairy proteins, has raised $4 million in a funding round led by NYA Ventures and Nàdarra Ventures. The company's strategy diverges from how many fermentation startups have traditionally approached scaling: instead of designing an ingredient and then figuring out how to manufacture it at scale, Aux Labs looked first at what manufacturing infrastructure already exists, then engineered its product around it.
Brewing capacity instead of bespoke plants
The company is using existing brewing facilities in North America rather than building dedicated production plants. "Rather than build out a lot of these bespoke systems, we're trying to utilize more traditional fermentation capacity in order for us to actually scale," CEO and founder Ted Jin said. This approach sidesteps the capital drain that has plagued other fermentation startups in a tighter funding environment.
Nàdarra Ventures managing partner Mary Dimou emphasized that at the seed stage, using existing infrastructure is essential. "At the seed stage of investment, it's an absolute necessity to use existing infrastructure, otherwise startups will struggle to build a credible product," she said.
Casein for mozzarella performance
Aux Labs produces casein, the key protein in cheese, positioning itself alongside other casein makers like Better Dairy and New Culture. The company is targeting mozzarella, a category many alt-dairy companies pursue because of how difficult it is to replicate melt and stretch performance.
Performance is the core message. Jin stated that sustainability alone will not drive adoption: "Performance is the decisive factor. If it doesn't deliver at the end of the day, they're not going to come back." The company has drawn lessons from earlier alternative protein failures around positioning, launch strategy and consumer education.
Three non-negotiables for mainstream adoption
Aux Labs emphasizes three factors needed to compete mainstream: taste, function and price. The company believes it has addressed the first two but acknowledged that price parity to conventional cheese remains a work in progress.
During tasting events, Jin noted that the appeal extends beyond vegans: "It was not just for vegans … the majority just wanted to try it." The company is open to multiple routes to market, including foodservice, retail or CPG partnerships.
The ingredient-platform shift
Dimou sees Aux Labs as part of a broader reset in alternative protein. Rather than selling finished products, the next wave will focus on ingredients that larger CPG companies can use for reformulation and cleaner labels. Dimou explained that the ingredient approach "allows the larger corporate … to build up a new SKU with your one ingredient versus an end product."
The global dairy system is facing pressure from climate stress, herd health and constrained production, creating room for new technologies. Aux Labs' underlying protein platform extends beyond dairy, giving it flexibility to adapt to different market needs, Dimou said. "Aux Labs is more than just a dairy company. There's this underlying protein platform itself, which is highly flexible. It's not a single category company."